/
QGEN
$39.44-$0.35 (-0.89%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$8.1B
206M shares
52-week range
$32.53 – $57.82
27% from low
Exchange
NYSE
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-12.56
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.50B | $1.53B | $1.87B | $2.25B | $2.14B | $1.97B | $1.98B | $2.09B |
| Cost of revenue | $500.9M | $521.2M | $637.6M | $800.8M | $757.0M | $731.6M | $1.01B | $798.5M |
| Gross profit | $1.00B | $1.01B | $1.23B | $1.45B | $1.38B | $1.23B | $967.4M | $1.29B |
| Gross margin | 66.6% | 65.9% | 65.9% | 64.4% | 64.7% | 62.8% | 48.9% | 61.8% |
| R&D | $161.9M | $157.4M | $149.1M | $190.0M | $189.9M | $198.5M | $193.5M | $187.5M |
| Operating income | $266.6M | −$26.1M | $386.4M | $630.1M | $531.5M | $409.9M | $97.7M | $520.3M |
| EBITDA | $499.5M | $227.9M | $715.8M | $895.2M | $779.4M | $688.6M | $368.3M | $717.3M |
| Net income | $190.4M | −$41.5M | $359.2M | $512.6M | $423.2M | $341.3M | $83.6M | $424.9M |
| Net margin | 12.7% | -2.7% | 19.2% | 22.8% | 19.8% | 17.4% | 4.2% | 20.3% |
| EPS (diluted) | 0.82 | -0.19 | 0.32 | 2.47 | 2.05 | 1.65 | 0.38 | 2.04 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.1B | $2.42 | $2.36–$2.48 | 9 |
| 2027 | $2.3B | $2.62 | $2.56–$2.73 | 9 |
| 2028 | $2.4B | $2.86 | $2.56–$3.71 | 5 |
| 2029 | $2.5B | $3.11 | $3.04–$3.24 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$70.14
Price
$39.44
Implied upside
+78%
Peer comparison
QIAGEN N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
www.qiagen.com- Employees
- 5,500
- IPO / List date
- Jun 28, 1996
Held by traders on TradeandTell
No one on the platform currently holds QGEN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in QGEN as of their last filing.
Insider activity (SEC Form 4)
Dividend history
TTM yield · 10.52% ($4.15/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-07 | $0.3500 | 2026-07-14 |
| 2026-01-08 | $2.2900 | |
| 2025-07-02 | $0.2500 | 2025-07-10 |
| 2025-01-29 | $1.2600 |
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-01-29 | 35-for-36reverse |
| 2024-01-30 | 24.25-for-25reverse |
| 2017-01-25 | 26-for-27reverse |
Recent trades on TradeandTell
No one on the platform has traded QGEN yet.
